ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Ponatinib, a third-generation TKI, specifically targets the challenging T315I mutation, which confers high resistance to CML cells by altering the ATP-binding domain of BCR::ABL1 [12].